Indian stocks: Visit www.stage2stocks.com →

HCW Biologics Inc.

Stage 4 · Declining · week 12

As of Oct 22, 2026, HCW Biologics is in Stage 4, the downtrend phase, now in week 12 (since Aug 4, 2026). It closed at $1.12, 95.2% below its 52-week high and below its 200-day average, which is falling.

HCW Biologics Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing novel immunotherapies for chronic, low-grade inflammation, and diseases in the United States. More about the company

$1.12
-7.44% today
$2.5M · Micro cap
Market Neutral — Building

Pro read

Pro

Our read

Declining, below its long-term trend

Setup score

—

Momentum

Steady

Edge

—

Is HCWB early, or has it already run? Pro answers that for every US stock we cover, after every close.

Get Pro · $19 a month

Renews monthly until you cancel. Cancel any time in Plan & billing.

Loading price chart…
Stage Cycle Timeline2023-08-16 → 2026-10-22
S4 14w
S4 27w
S4 39w
S4 33w
2023-08-162026-10-22
S1S2S3S4Setup score (0–10, dashed line at 5)
S2 3w → S3 10w → S4 14w → S1 10w → S2 2w → S1 1w → S4 27w → S1 4w → S4 39w → S1 1w → S4 33w → S1 11w → S4 11w current
Total tracked: 166 weeks across 13 stage runs.

HCWB among Biotechnology532nd of 591 by relative strength

All 591 →
Stocks in Biotechnology ranked by relative strength, with stage and one-month change
#StockStageRS1M
1GTBPStage 2 · wk 799−22.3%
2IOVAStage 2 · wk 1899+38.8%
3SLSStage 3 · wk 499−1.5%
4MRNAStage 2 · wk 1799+11.3%
5TWSTStage 2 · wk 3999−14.5%
6KODStage 2 · wk 499+172.1%
7ERASStage 3 · wk 599+0.7%
8CLYMStage 3 · wk 399−15.8%
…532HCWBStage 4 · wk 125−32.5%
vs 52W High
-95.2%
$1.12 lo$23.52 hi
95.2% below 52W high, deep Stage 4 damage
In Stage 4, distance from the 52-week high reflects an ongoing decline, not a discount.
Stage Maturity
Week 12
1w13w26w
Week 12, established downtrend
How long this stock has been in Stage 4 decline. The longer the downtrend, the more entrenched the selling pressure. No length of decline marks a bottom on its own.
vs 200 DMA
-74.0%
200 DMA: $4.30 · sloping down
In Stage 4, the stock is below its 200-day average, the hallmark of a downtrend. Stage analysis waits for that to reverse before buying.
Rel Volume
0.09x
vs 50-day avg
High volume on down days in Stage 4 confirms institutional selling. Low-volume bounces are typical. They lack real buyers and are easy to mistake for reversals.
Trend Health
↓
Short-term trend rolling over
Two reads of momentum. The arrow shows the direction of the short-term trend: rising (↑ or ↗), flat (→) or rolling over (↓). The ⇈ mark appears when our trend model reads the move as gaining speed on top of the longer trend. Strongest when both agree.
1M
-32.5%
3M
-55.2%
6M
-54.4%
YTD
-83.3%
1Y
-95.3%
Scan Membership
Breakout Watch
Latest: 2024-05-03
3 appearances in last 60 days. First seen: 2022-09-06.
A stock that keeps qualifying week after week does so because its Stage 2 structure keeps holding. Staying power in the scan says more about the trend than any single appearance.
Recent Stage Timeline
2026-10-22S4
Wk 12 · Vol 0.09x
2026-10-21S4
Wk 12 · Vol 0.10x
2026-10-20S4
Wk 11 · Vol 0.19x
2026-10-19S4
Wk 11 · Vol 0.20x
2026-10-16S4
Wk 11 · Vol 0.16x
2026-10-15S4
Wk 11 · Vol 0.10x
2026-10-14S4
Wk 11 · Vol 0.11x
2026-10-13S4
Wk 10 · Vol 4.59x
2026-10-12S4
Wk 10 · Vol 0.09x
2026-10-09S4
Wk 10 · Vol 0.17x
2026-10-08S4
Wk 10 · Vol 0.10x
2026-10-07S4
Wk 10 · Vol 0.07x
Moving averages & range
50 DMA
$2.08
200 DMA
$4.30
52W High
$23.52
52W Low
$1.12
5D Low
$1.12
Resistance levels (recent highs)
20d High
$1.93
60d High
$3.60
120d High
$17.34
250d High
$23.52
Next resistance
+72.3%
to 20d High
ROE
-151.4%
Profit margin -83.0%
Dividend Yield
0.00%
P/B 0.2

HCW Biologics: quick answers

What stage is HCW Biologics in?

As of Oct 22, 2026, HCW Biologics (HCWB) is in Stage 4, the downtrend phase. It entered Stage 4 on Aug 4, 2026 and is in week 12. What the four stages mean

Is HCW Biologics in an uptrend?

No. HCW Biologics is in a Stage 4 downtrend. It trades 74.0% below its 200-day average, which is falling.

How far is HCW Biologics from its 52-week high?

HCW Biologics closed at $1.12 on Oct 22, 2026, 95.2% below its 52-week high of $23.52. Its 52-week low is $1.12.

How has HCW Biologics performed over the past year?

As of Oct 22, 2026, HCW Biologics is down 95.3% over the past year and down 83.3% so far in 2026.

Which sector and industry is HCW Biologics in?

HCW Biologics is in the Biotechnology industry, part of the Health Care sector.

About this companyHealth Care· Biotechnology

HCW Biologics Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing novel immunotherapies for chronic, low-grade inflammation, and diseases in the United States. Its lead products include HCW11-018b, a novel, tetra-valent T-Cell engager; HCW11-040, a multifunctional fusion molecule that is a combination of cytokines and pembrolizumab; and HCW9302, injectable and interleukin 2 (IL-2) fusion protein complex, which is in clinical trial in patients with alopecia areata diseases. The company also develops HCW9201, a fusion protein designed as a reagent to use in the production of natural killer (NK) cell-based therapies; HCW9206, a fusion protein designed as a reagent to use in the production of CAR-therapies for the treatment of infectious diseases; and HCW11-006, a multi-functional immune cell stimulator. It has a license agreement with Wugen Inc. to develop cell therapy-based treatments; and a license, research and co-development agreement with WY Biotech Co., Ltd. for its preclinical molecule. HCW Biologics Inc. was incorporated in 2018 and is headquartered in Miramar, Florida.

Visit company website →

All analytics based on EOD data. Data as of 2026-10-22. Past data patterns are not indicative of future results. This page is a data analytics tool only.